PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Pricing and Reimbursement: Risk and Opportunity in Pharmaceutical Deal Making
From issue 87 of the PharmaDeals Review (2007-09-01)
A recently published report from PharmaVentures, with the same title as this article, focuses on the critical application of the challenging political and market environment within the specific context of pricing and reimbursement (P&R) in the process of deal making in the pharmaceutical industry. The in-licensing of new drugs has increased dramatically over the past 30 years, and as deal making has intensified, the nature of deals has changed, and issues such as market dynamics and the uncertainty around future pricing have increased in profile. This can affect the valuation of licensing deals, and the message coming clearly from P&R dynamics is that traditional models need frequent revision. This article takes a look at three of the nine chapters of the report: those on the current P&R environment (Chapter 3), pharmacoeconomics and the future for pricing value (Chapter 7), and solutions for deal makers – the last chapter, which gives advice on valuation components and future drivers of value.
Available as PDF
(Subscribers only)
Therapy Focus: Diagnosing Prostate Cancer
From issue 87 of the PharmaDeals Review (2007-09-01)
The timely and accurate diagnosis of prostate cancer is essential in catching it early, which emphasises the importance of reliable diagnostics. It is no surprise, then, that prostate cancer screening sales are worth approximately US$350 M annually, and that there have been a minimum of 60 prostate cancer diagnostic deals over the past 10 years, as recorded in PharmaDeals® Agreements. This feature examines the currently available tests, and some of those that are emerging, as well as the deals and companies concerning them, and also discusses the importance of discovering specific prostate cancer biomarkers.
Available as PDF
(Subscribers only)
Novartis' Vaccine Boost
From issue 86 of the PharmaDeals Review (2007-08-01)
The vaccine market is becoming more important to big pharma's business, which has resulted in larger deals being made in this area, as exemplified by the recent partnership between Intercell and Novartis. Aspects of the deal discussed in this feature include the role played by Novartis Vaccines within the company, the key role of flu vaccines in its vaccine business, the HCV co-development part of the deal, Novartis' opt-in rights, and the financial freedom that Intercell has to work within the alliance.
Available as PDF
(Subscribers only)
Roche and AstraZeneca Join the RNAi Race
From issue 86 of the PharmaDeals Review (2007-08-01)
The potential to deliver both life-saving and financially lucrative medicines has put RNA interference (RNAi) on the must-have lists of major pharmas. The majority of key IP is held by a relatively small number of entities, giving them bargaining power which has resulted in a series of high-value deals. This article looks at the recent deals made between Roche and Alnylam Pharmaceuticals, and AstraZeneca and Silence Therapeutics (formerly SR Pharma) in their bids to join the RNAi race.
Available as PDF
(Subscribers only)
How Companies Source their Licensing Opportunities, Part III: PharmaVentures's Approach to Increasing the Quality of the Target Candidate List and the Speed of the Licensing Process
From issue 86 of the PharmaDeals Review (2007-08-01)
In this last of our three-part series, Tibor Papp, Head of the Consultancy Group at PharmaVentures, looks at the approach taken by this Group in assisting small-to-medium sized companies to increase their target candidate list and speed up the subsequent licensing process. He addresses the key challenges faced by such companies in licensing products, the screening, qualifying and evaluation process for partners, and the striking of an optimal deal.
Last Issue PDF
RSS